NCMR is a subsidiary of e-Solutions Co. and engaged in R&D of regenerative medicine products for the treatment of acute cerebral infaction (NCS-01). The mesenchymal stem cells (MSC) are derived from human bone marrow. The present thrombolytic therapy for acute cerebral infaction is limited to within 4,5 hours after the onset, whereas MSC can be applied over an extended period. Clinical trials in Japan and the USA are planned for 2018.
NC Medical Research news release, September 27, 2017